Tumeurs rares du tube digestif et du péritoine

  • J. Desramé
  • D. Béchade
  • T. Lecomte
  • B. Landi
Part of the Oncologie Pratique book series (ONCOLPRAT)


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Miettinen M, Lasota J (2001) Gastrointestinal stromal tumors — definition, clinical, histological, immunohistochemical and molecular features and differential diagnosis. Virchows Arch 438: 1–12CrossRefPubMedGoogle Scholar
  2. 2.
    Fletcher CD, Berman J, Corless C et al. (2002) Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33: 459–65PubMedGoogle Scholar
  3. 3.
    Rubin BP, Singer S, Tsao C et al. (2001) KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 61: 8118–21PubMedGoogle Scholar
  4. 4.
    Corless CL, McGreevey L, Haley A et al. (2002) KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 160: 1567–72PubMedGoogle Scholar
  5. 5.
    Hirota S, Isozaki K, Moriyama Y et al. (1998) Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577–80CrossRefPubMedGoogle Scholar
  6. 6.
    Kindblom LG, Meis-Kindblom J, Bümming P et al. (2002) Incidence, prevalence, phenotype, and biologic spectrum of gastrointestinal stromal tumors: a population based study of 600 cases. Ann Oncol 13: 577 (abstract)Google Scholar
  7. 7.
    Pidhorecky I, Cheney RT, Kraybill WG, Gibbs JF (2000) Gastrointestinal stromal tumors: current diagnosis, biologic behavior, and management. Ann Surg Oncol 7: 705–12PubMedGoogle Scholar
  8. 8.
    Miettinen M, El-Rifai W, Sobin LH, Lasota J (2002) Evaluation of malignancy and prognosis of gastrointestinal stromal tumors: a review. Hum Pathol 33: 478–83PubMedGoogle Scholar
  9. 9.
    Chak A (2002) EUS in submucosal tumors. Gastrointest Endosc 56(suppl): S43–S48PubMedGoogle Scholar
  10. 10.
    Palazzo L, Landi B, Cellier C et al. (2000) Endosonographic features predictive of benign and malignant smooth muscle tumors. Gut 46: 88–92CrossRefPubMedGoogle Scholar
  11. 11.
    Burkill GJ, Badran M, Al-Muderis M et al. (2003) Malignant gastrointestinal stromal tumors: distribution, imaging features, and pattern of metastatic spread. Radiology 226: 527–32PubMedGoogle Scholar
  12. 12.
    Ando N, Goto H, Niwa Y et al. (2002) The diagnosis of GI stromal tumors with EUS-guided fine needle aspiration with immunohistochemical analysis. Gastrointest Endosc 55: 37–43CrossRefPubMedGoogle Scholar
  13. 13.
    Ludwig DJ, Traverso LW (1997) Gut stromal tumors and their clinical behavior. Am J Surg 173: 390–4.CrossRefPubMedGoogle Scholar
  14. 14.
    Joensuu H, Fletcher C, Dimitrijevic S et al. (2002) Management of malignant gastrointestinal stromal tumours. Lancet Oncol 3: 655–6CrossRefPubMedGoogle Scholar
  15. 15.
    Dematteo RP, Lewis JJ, Leung D et al. (2000) Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 231: 51–8CrossRefPubMedGoogle Scholar
  16. 16.
    Dematteo RP, Heinrich MC, El-Rifai WM, Demetri G (2002) Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol 33: 466–77CrossRefPubMedGoogle Scholar
  17. 17.
    Matthews BD, Walsh RM, Kercher KW et al. (2002) Laparoscopic versus open resection of gastric stromal tumors. Surg Endosc 16: 803–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Yao KA, Talamonti MS, Langella RL et al. (2000) Primary gastrointestinal sarcomas: analysis of prognostic factors and results of surgical management. Surgery 128: 604–12CrossRefPubMedGoogle Scholar
  19. 19.
    Plaat BE, Hollema H, Molenaar WM (2000) Soft tissue leiomyosarcomas and malignant gastrointestinal stromal tumors: differences in clinical outcome and expression of multidrug resistance proteins. J Clin Oncol 18: 3211–20PubMedGoogle Scholar
  20. 20.
    Edmonson J, Marks R, Buckner J (1999) Contrast of Response to D-MAP + Sargramostim Between Patients with Advanced Malignant Gastrointestinal Stromal Tumors and Patients with Other Advanced Leiomyosarcomas. Proc of the Am Soc of Clin Oncol: abstract 2088Google Scholar
  21. 21.
    Rajan DK, Soulen MC, Clark TW et al. (2001) Sarcomas metastatic to the liver: response and survival after cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol chemoembolization. J Vasc Interv Radiol 12: 187–93PubMedGoogle Scholar
  22. 22.
    Eilber FC, Rosen G, Forscher C et al. (1999) Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas. Ann Surg Oncol 6: 645–50CrossRefPubMedGoogle Scholar
  23. 23.
    Joensuu H, Roberts PJ, Sarlomo-Rikala M et al. (2001) Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344: 1052–6CrossRefPubMedGoogle Scholar
  24. 24.
    van Oosterom AT, Judson I, Verweij J et al. (2001) Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358: 1421–3PubMedGoogle Scholar
  25. 25.
    Demetri GD, Von Mehren M, Blanke CD et al. (2002) Efficacy and safety of imatinib in advanced gastrointestinal stromal tumors. N Engl J Med 347: 472–80CrossRefPubMedGoogle Scholar
  26. 26.
    Verweij J, Casali PG, J Zalcberg J et al. (2003) Early efficacy comparison of two doses of imatinib for the treatment of advanced gastro-intestinal stromal tumors (GIST): interim results of a randomized phase III trial from the EORTC-STBSG, ISG and AGITG. Proc Am Soc Clin Oncol 22: a3272 (abstract)Google Scholar
  27. 27.
    Zalcberg JR, Verweij J, Casali PG et al. (2004) Outcome of patients with advanced gastrointestinal stromal tumors (GIST) crossing over to a daily imatinib dose of 800 mg (HD) after progression on 400 mg (LD)-an international, intergroup study of the EORTC, ISG and AGITG. Proc Am Soc Clin Oncol 23: a9004 (abstract)Google Scholar
  28. 28.
    Benjamin RS, Rankin C, Fletcher C et al. (2003) Phase III dose-randomized study of imatinib mesylate (Glivec, STI571) for GIST: Intergroup S0033 early results. Proc Am Soc Clin Oncol 22: a3271 (abstract)Google Scholar
  29. 29.
    Rankin C, Von Mehren M, Blanke C et al. (2004) Dose effect of imatinib (IM) in patients with metastatic GIST-Phase III sarcoma group study S0033. Proc Am Soc Clin Oncol 23: a9005 (abstract)Google Scholar
  30. 30.
    van Oosterom AT, Judson IR, Verweij J et al. (2002) Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 38Suppl 5: S83–7PubMedGoogle Scholar
  31. 31.
    Blay JY, Berthaud P, Perol D et al. (2004) Continuous versus intermittent imatinib treatment in advanced GIST after one year: a prospective randomized phase III trial of the French sarcoma group. Proc Am Soc Clin Oncol 23: a9006 (abstract)Google Scholar
  32. 32.
    Stroobants S, Goeminne J, Seegers M et al. (2003) 18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate. Eur J Cancer 39: 2012–20CrossRefPubMedGoogle Scholar
  33. 33.
    Heinrich MC, Corless CL, Blanke CD et al. (2003) PDGFRA and KIT mutations correlate with the clinical responses to imatinib mesylate in patients with advanced gastrointestinal stromal tumors. Proc Am Soc Clin Oncol 22: a3274 (abstract)Google Scholar
  34. 34.
    Heinrich MC, Corless CL, Duensing A et al. (2003) PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299: 708–10CrossRefPubMedGoogle Scholar
  35. 35.
    Shields CJ, Winter DC, Kirwan WO, Redmond HP (2001) Desmoids tumours. Eur J Surg Oncol 27: 701–6CrossRefPubMedGoogle Scholar
  36. 36.
    Ballo MT, Zagars GK, Pollack A et al. (1999) Desmoid tumor: prognostic factors and outcome after surgery, radiation therapy, or combined surgery and radiation therapy. J Clin Oncol 17: 158–67PubMedGoogle Scholar
  37. 37.
    Burke AP, Sobin HL, Shekitka KM et al. (1990) Intra-abdominal fibromatosis. A pathological analysis of 130 tumors with comparaison of clinical subgroups. Am J Surg Pathol 1990 14: 335–41PubMedGoogle Scholar
  38. 38.
    Lofti AM, Dozois RR, Gordon H et al. (1989) Desmoids tumor Mesenteric fibromatosis complicating familial adenomatous polyposis: predispositing factors and results of treatment. Int J Colorectal Dis 4: 30–6Google Scholar
  39. 39.
    Mace J, Biermann JS, Sondak V et al. (2002) Response of extraabdominal desmoid tumors to therapy with ImatinibMesylate. Cancer 95: 2373–9CrossRefPubMedGoogle Scholar
  40. 40.
    Elias D, Prezioso GP, Goahrin A et al. (2000) Treatment of desmoid mesenteric. Press Med 29: 408–12Google Scholar
  41. 41.
    Okuno SH, Edmonson JH (2003) Combination chemotherapy for desmoid tumors. Cancer 97: 1134–5PubMedGoogle Scholar
  42. 42.
    Mannant PR, Beau P, de Lédinghen V et al. (1995) Regression partielle d’une tumeur desmoïde après traitement prolongé par le lanréotide. Gastroenterol Clin Biol 19: 1072–3PubMedGoogle Scholar
  43. 43.
    Barraya R, Benhamiche AM, Rassiat E et al. (1999) Incidence and management of cancers of the small bowel in Burgundy (France). Gastroenterol Clin Biol 23: 215–20PubMedGoogle Scholar
  44. 44.
    Dabaja B, Suki D, Pro B et al. (2004) Adenocarcinoma of the small bowel. Presentation, prognostic factors and outcome of 217 patients. Cancer 101: 518–26CrossRefPubMedGoogle Scholar
  45. 45.
    Howe JR, Karnell LH, Menck HR, Scott-Conner C (1999) Adenocarcinoma of the small bowel: review of the national data base, 1985–1995. Cancer 86: 2693–706CrossRefPubMedGoogle Scholar
  46. 46.
    Talamonti MS, Goetz LH, Rao S, Joehl RJ (2002) Primary cancers of the small bowel. Arch Surg 137: 564–71PubMedGoogle Scholar
  47. 47.
    North JH, Pack MS (2000) Malignant tumors of the small intestine: a review of 144 cases. Am Surg 66: 46–51PubMedGoogle Scholar
  48. 48.
    Rose DM, Hochwald SN, Klimstra DS, Brennan MF (1996) Primary duodenal adenocarcinoma: a ten years experience with 79 patients. J Am Coll Surg 183: 89–6PubMedGoogle Scholar
  49. 49.
    Fenoglio-Preiser CM (1999) Gastro-Intestinal Pathology Plus: an atlas and text. CD Rom version. Lippincott Williams and Willkins Publications Hagerstown-Maryland USAGoogle Scholar
  50. 50.
    Zollinger RM, Sternfeld W, Schreiber H (1986) Primary neoplasms of the small intestine. Am J Surg 151: 654–8CrossRefPubMedGoogle Scholar
  51. 51.
    Orjollet-Lecoanet C, Ménard Y, Martins A et al. (2000) CT enteroclysis for detection of small bowel tumors. J Radiol 81: 618–27PubMedGoogle Scholar
  52. 52.
    Miossec S, Parc R, Paye F (2004) Ampullectomy in benign lesion: indications and results. Ann Chir 129: 73–8CrossRefPubMedGoogle Scholar
  53. 53.
    American Joint Committee on Cancer (1997) Manual Staging of Cancer, 5th edition, Lippincott-Raven, Philadelphia USAGoogle Scholar
  54. 54.
    Abrams R, Grochow LB, Chakravarthy A et al. (1999) Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA 19.9 levels. Int J Radiation Oncology Biol Phys 44: 1039–46CrossRefGoogle Scholar
  55. 55.
    Coia L, Hoffman J, Scher R et al. (1994) Preoperative chemoradiation for adenocarcinoma of the pancreas and duodenum. Int J Radiation Oncology Biol Phys 44: 161–7Google Scholar
  56. 56.
    Ouriel K, Adams JT (1984) Adenocarcinoma of the small intestine. Am J Surg 147: 66–71CrossRefPubMedGoogle Scholar
  57. 57.
    Jigyasu D, Bedikian Y, Stroehlein JR (1984) Chemotherapy for primary adenocarcinoma of the small bowel. Cancer 53: 23–5PubMedGoogle Scholar
  58. 58.
    Crawley C, Ross P, Norman A, Cunningham D (1998) The royal Marsden experience of small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil. Br J Cancer 78: 508–10PubMedGoogle Scholar
  59. 59.
    Locher C, Boige V, Kergoat P et al. (2001) Résultats de l’association 5-Fluoro-uracile (5-Fu)/sel de platine dans les adénocarcinomes du grêle localement avancés et/ou métastatiques. Gastroenterol Clin Biol 25: A182Google Scholar
  60. 60.
    Ducreux M, Rougier P, Pignon JP et al. (2002) A randomised trial comparing 5-Fu with 5-Fu plus cisplatin in advanced pancreatic carcinoma. Ann Oncol 13: 1185–91CrossRefPubMedGoogle Scholar
  61. 61.
    Elias D, Sabourin JC (1999) Pseudomyxoma peritonei. A review. J Chir 136: 341–7Google Scholar
  62. 62.
    Elias D, Laurent S, Antoun S et al. (2003) Pseudomyxoma peritoneal treated with complete resection and immediate intraperitoneal chemotherapy. Gastroenterol Clin Biol 27: 407–12PubMedGoogle Scholar
  63. 63.
    Ronnett BM, Shmookler BM, Sugarbaker PH, Kurman RJ (1997) Pseudomyxoma peritonei: new concepts in diagnosis, origin, nomenclature, and relationship to mucinous borderline tumors of the ovary. Anat Pathol 2: 197–226PubMedGoogle Scholar
  64. 64.
    Ronnett BM, Zahn CM, Kurman RJ et al. (1995) Disseminated peritonal adnomucinosis and peritoneal mucinous carcinomatosis. A clinicopathologic analysis of 109 cases with emphasis on distinguishing pathologic features, site of origin, prognosis, and relationship to “pseudomyxoma peritonei”. Am J Surg Pathol 19: 1390–408PubMedGoogle Scholar
  65. 65.
    Hinson FL, Ambrose S (1998) Pseudomyxoma peritonei. Review. Br J Surg 85: 1332–9Google Scholar
  66. 66.
    Smith JW, Kemeny N, Caldwell C et al. (1992) Pseudomyxoma peritonei of appendiceal origin. The Memorial Sloan-Kettering Cancer Center Experience. Cancer 7: 396–401Google Scholar
  67. 67.
    Elias D, Ouellet JF (2001) Intraperitoneal chemohyperthermia. Rationale, technique, indications, and results. Surg Oncol Clin North Am 10: 915–33Google Scholar
  68. 68.
    Sugarbaker PH, Shmookler B, Ronnett BM, Chang D (1999) Pseudomyxoma peritonei. Br J Surg 86: 842PubMedGoogle Scholar
  69. 69.
    Sugarbaker PH (2001) Cytoreductive surgery and peri-operative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome. Eur J Surg Oncol 27: 239–43PubMedGoogle Scholar
  70. 70.
    Britton M (2002) The epidemiology of mesothelioma. Semin Oncol 29: 18–25CrossRefPubMedGoogle Scholar
  71. 71.
    Carbone M, Kratzke RA, Testa JR (2002) The pathogenesis of mesothelioma. Semin oncol 29: 2–17CrossRefPubMedGoogle Scholar
  72. 72.
    Sugarbaker PH, Acherman YIZ, Gonzalez-Moreno S et al. (2002) Diagnosis and treatment of peritoneal mesothelioma: The Washington Cancer Institute experience. Semin Oncol 29: 51–61CrossRefPubMedGoogle Scholar
  73. 73.
    Baas P (2002) Chemotherapy for maligant mesothelioma: from doxorubicin to vinorelbine. Semin Oncol 29: 62–69CrossRefPubMedGoogle Scholar
  74. 74.
    Nowak AK, Byrne MJ, Williamson R et al. (2002) A multicentre phase II study of cisplatine and gemcitabine for malignant mesothelioma. Br J Cancer 87: 491–6CrossRefPubMedGoogle Scholar
  75. 75.
    Vogelzang NJ, Rusthoven JJ, Symanowski J et al. (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21: 2636–44CrossRefPubMedGoogle Scholar
  76. 76.
    Feldman AL, Libutti SK, Pingpank JF et al. (2003) Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 21: 4560–7CrossRefPubMedGoogle Scholar
  77. 77.
    Antmann K Shemin R, Ryan L (1988) Malignant mesothelioma: Prognosis variables in a registry of 180 patients, the Dana-Farber Cancer Institute and Brigham and Women’s Hospital experience over two decades. J Clin Oncol 6: 147–53Google Scholar
  78. 78.
    Kerrigan SA, Turnnir RT, Clement PB (2002) Diffuse malignant epithelial mesotheliomas of the peritoneum in women: A clinicopathologic study of 25 patients. Cancer 94: 378–85Google Scholar
  79. 79.
    Sebbag G, Sugarbaker PH (2001) Peritoneal mesothelioma proposal for a staging system. Eur J Surg Oncol 27: 223–4CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag France 2006

Authors and Affiliations

  • J. Desramé
  • D. Béchade
  • T. Lecomte
  • B. Landi

There are no affiliations available

Personalised recommendations